よむ、つかう、まなぶ。
参考資料4 有効性評価に基づく子宮頸がん検診ガイドライン更新版2020年３月31日 (64 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_25869.html |
| 出典情報 | がん検診のあり方に関する検討会（第35回 5／25）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
51) Kamineni A, Weinmann S, Shy KK, Glass AG, Weiss NS. Efficacy of screening in
preventing cervical cancer among older women. Cancer Causes Control. 2013; 24(9):
1653-1660.
52) Zappa M, Visioli CB, Ciatto S, Iossa A, Paci E, Sasieni P. Lower protection of
cytological screening for adenocarcinomas and shorter protection for younger women: the
results of a case-control study in Florence. Br J Cancer. 2004; 90(9): 1784-1786.
53) 厚生労働省: 平成 28 年度地域保健・健康増進事業報告. 閲覧(健康増進編)市区町村表.
平成 27 年度における子宮頸がん検診受診者数・要精密検査者数・精密検査受診の有無別人数、
偶発症の有無別人数、市区町村、検診方式・検診回数・年齢階級別(総数)2018/03/07 公開版
54) Katki HA, Kinney WK, Fetterman B, Lorey T, Poitras NE, Cheung L, Demuth F,
Schiffman M, Wacholder S, Castle PE. Cervical cancer risk for women undergoing
concurrent testing for human papillomavirus and cervical cytology: a population-based
study in routine clinical practice. Lancet Oncol. 2011; 12(7): 663-672.
55) Malagón T, Kulasingam S, Mayrand MH, Ogilvie G, Smith L, Bouchard C, Gotlieb
W, Franco EL. Age at last screening and remaining lifetime risk of cervical cancer in
older, unvaccinated women: a modelling study. Lancet Oncol. 2018; 19(12): 1569-1578.
56) Cervix Cancer Screening. IARC Handbooks of Cancer Prevention Volume 10. IARC.
Press Lyon. 2005; 175-180.
57) Meggiolaro A, Unim B, Semyonov L, Miccoli S, Maffongelli E, La Torre G. The role of
Pap test screening against cervical cancer: a systematic review and meta-analysis. Clin
Ter. 2016; 167(4): 124-139.
58) IARC Working Group on evaluation of cervical cancer screening programmes.
Screening for squamous cervical cancer: duration of low risk after negative results of
cervical cytology and its implication for screening policies. Br Med J (Clin Res Ed). 1986;
293(6548): 659-664.
59) van den Akker-van Marle ME, van Ballegooijen M, Habbema JD. Low risk of cervical
cancer during a long period after negative screening in the Netherlands. Br J Cancer.
2003; 88(7): 1054-1057.
60) Sasieni P, Adams J, Cuzick J. Benefit of cervical screening at different ages: evidence
from the UK audit of screening histories. Br J Cancer. 2003; 89(1): 88-93.
61) Makino H, Sato S, Yajima A, Komatsu S, Fukao A. Evaluation of the effectiveness of
cervical cancer screening: a case-control study in Miyagi, Japan. Tohoku J Exp Med.
1995; 175(3): 171-178.
62) Hoffman M, Cooper D, Carrara H, Rosenberg L, Kelly J, Stander I, Williamson AL,
Denny L, du Toit G, Shapiro S. Limited Pap screening associated with reduced risk of
cervical cancer in South Africa. Int J Epidemiol. 2003; 32(4): 573-577.
preventing cervical cancer among older women. Cancer Causes Control. 2013; 24(9):
1653-1660.
52) Zappa M, Visioli CB, Ciatto S, Iossa A, Paci E, Sasieni P. Lower protection of
cytological screening for adenocarcinomas and shorter protection for younger women: the
results of a case-control study in Florence. Br J Cancer. 2004; 90(9): 1784-1786.
53) 厚生労働省: 平成 28 年度地域保健・健康増進事業報告. 閲覧(健康増進編)市区町村表.
平成 27 年度における子宮頸がん検診受診者数・要精密検査者数・精密検査受診の有無別人数、
偶発症の有無別人数、市区町村、検診方式・検診回数・年齢階級別(総数)2018/03/07 公開版
54) Katki HA, Kinney WK, Fetterman B, Lorey T, Poitras NE, Cheung L, Demuth F,
Schiffman M, Wacholder S, Castle PE. Cervical cancer risk for women undergoing
concurrent testing for human papillomavirus and cervical cytology: a population-based
study in routine clinical practice. Lancet Oncol. 2011; 12(7): 663-672.
55) Malagón T, Kulasingam S, Mayrand MH, Ogilvie G, Smith L, Bouchard C, Gotlieb
W, Franco EL. Age at last screening and remaining lifetime risk of cervical cancer in
older, unvaccinated women: a modelling study. Lancet Oncol. 2018; 19(12): 1569-1578.
56) Cervix Cancer Screening. IARC Handbooks of Cancer Prevention Volume 10. IARC.
Press Lyon. 2005; 175-180.
57) Meggiolaro A, Unim B, Semyonov L, Miccoli S, Maffongelli E, La Torre G. The role of
Pap test screening against cervical cancer: a systematic review and meta-analysis. Clin
Ter. 2016; 167(4): 124-139.
58) IARC Working Group on evaluation of cervical cancer screening programmes.
Screening for squamous cervical cancer: duration of low risk after negative results of
cervical cytology and its implication for screening policies. Br Med J (Clin Res Ed). 1986;
293(6548): 659-664.
59) van den Akker-van Marle ME, van Ballegooijen M, Habbema JD. Low risk of cervical
cancer during a long period after negative screening in the Netherlands. Br J Cancer.
2003; 88(7): 1054-1057.
60) Sasieni P, Adams J, Cuzick J. Benefit of cervical screening at different ages: evidence
from the UK audit of screening histories. Br J Cancer. 2003; 89(1): 88-93.
61) Makino H, Sato S, Yajima A, Komatsu S, Fukao A. Evaluation of the effectiveness of
cervical cancer screening: a case-control study in Miyagi, Japan. Tohoku J Exp Med.
1995; 175(3): 171-178.
62) Hoffman M, Cooper D, Carrara H, Rosenberg L, Kelly J, Stander I, Williamson AL,
Denny L, du Toit G, Shapiro S. Limited Pap screening associated with reduced risk of
cervical cancer in South Africa. Int J Epidemiol. 2003; 32(4): 573-577.